Covestor Ltd Has $105,000 Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Covestor Ltd lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 134.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 2,573 shares of the biopharmaceutical company’s stock after buying an additional 1,476 shares during the quarter. Covestor Ltd’s holdings in Halozyme Therapeutics were worth $105,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Hillsdale Investment Management Inc. bought a new stake in Halozyme Therapeutics during the 1st quarter worth approximately $4,593,000. Edgestream Partners L.P. grew its position in Halozyme Therapeutics by 354.4% during the 1st quarter. Edgestream Partners L.P. now owns 65,306 shares of the biopharmaceutical company’s stock worth $2,657,000 after acquiring an additional 50,933 shares during the last quarter. Mizuho Markets Americas LLC grew its position in Halozyme Therapeutics by 2.2% during the 1st quarter. Mizuho Markets Americas LLC now owns 456,636 shares of the biopharmaceutical company’s stock worth $18,576,000 after acquiring an additional 9,975 shares during the last quarter. Orion Portfolio Solutions LLC grew its position in Halozyme Therapeutics by 19.5% during the 1st quarter. Orion Portfolio Solutions LLC now owns 35,534 shares of the biopharmaceutical company’s stock worth $1,446,000 after acquiring an additional 5,809 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in Halozyme Therapeutics by 9.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 41,550 shares of the biopharmaceutical company’s stock worth $1,587,000 after acquiring an additional 3,500 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on HALO shares. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, July 16th. The Goldman Sachs Group increased their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Benchmark increased their price objective on Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Finally, JMP Securities decreased their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $58.38.

Insider Transactions at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total transaction of $519,300.00. Following the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $803,876.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 30,000 shares of company stock worth $1,473,200 in the last three months. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 2.9 %

Shares of NASDAQ:HALO traded up $1.60 during midday trading on Tuesday, hitting $55.94. The company had a trading volume of 670,952 shares, compared to its average volume of 1,253,500. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $56.00. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The stock has a market cap of $7.12 billion, a price-to-earnings ratio of 22.94, a PEG ratio of 0.55 and a beta of 1.27. The firm has a fifty day simple moving average of $49.39 and a 200 day simple moving average of $42.21.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The business had revenue of $195.88 million for the quarter, compared to analyst estimates of $201.72 million. On average, analysts predict that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.